These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32690723)

  • 21. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.
    Linnebacher M; Gebert J; Rudy W; Woerner S; Yuan YP; Bork P; von Knebel Doeberitz M
    Int J Cancer; 2001 Jul; 93(1):6-11. PubMed ID: 11391614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
    PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
    Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
    Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
    [No Abstract]   [Full Text] [Related]  

  • 24. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors.
    Woerner SM; Tosti E; Yuan YP; Kloor M; Bork P; Edelmann W; Gebert J
    Mol Carcinog; 2015 Nov; 54(11):1376-86. PubMed ID: 25213383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.
    Sveen A; Johannessen B; Tengs T; Danielsen SA; Eilertsen IA; Lind GE; Berg KCG; Leithe E; Meza-Zepeda LA; Domingo E; Myklebost O; Kerr D; Tomlinson I; Nesbakken A; Skotheim RI; Lothe RA
    Genome Med; 2017 May; 9(1):46. PubMed ID: 28539123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An immunogenic personal neoantigen vaccine for patients with melanoma.
    Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
    Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells.
    Saeterdal I; Gjertsen MK; Straten P; Eriksen JA; Gaudernack G
    Cancer Immunol Immunother; 2001 Nov; 50(9):469-76. PubMed ID: 11761441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TGFBR2-dependent alterations of exosomal cargo and functions in DNA mismatch repair-deficient HCT116 colorectal cancer cells.
    Fricke F; Lee J; Michalak M; Warnken U; Hausser I; Suarez-Carmona M; Halama N; Schnölzer M; Kopitz J; Gebert J
    Cell Commun Signal; 2017 Apr; 15(1):14. PubMed ID: 28376875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.
    Saeterdal I; Bjørheim J; Lislerud K; Gjertsen MK; Bukholm IK; Olsen OC; Nesland JM; Eriksen JA; Møller M; Lindblom A; Gaudernack G
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13255-60. PubMed ID: 11687624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability.
    Ishikawa T; Fujita T; Suzuki Y; Okabe S; Yuasa Y; Iwai T; Kawakami Y
    Cancer Res; 2003 Sep; 63(17):5564-72. PubMed ID: 14500396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
    Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
    Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy of non-microsatellite instability-high colorectal cancer.
    Shi R; Li Y; Ran L; Dong Y; Zhou X; Tang J; Han L; Wang M; Pang L; Qi Y; Wu Y; Gao Y
    Sci China Life Sci; 2022 Mar; 65(3):572-587. PubMed ID: 34236583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers.
    Kloor M; Becker C; Benner A; Woerner SM; Gebert J; Ferrone S; von Knebel Doeberitz M
    Cancer Res; 2005 Jul; 65(14):6418-24. PubMed ID: 16024646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical and molecular consequences of microsatellite instability in human cancers].
    Hamelin R; Chalastanis A; Colas C; El Bchiri J; Mercier D; Schreurs AS; Simon V; Svrcek M; Zaanan A; Borie C; Buhard O; Capel E; Zouali H; Praz F; Muleris M; Fléjou JF; Duval A
    Bull Cancer; 2008 Jan; 95(1):121-32. PubMed ID: 18230578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer.
    Bauer K; Michel S; Reuschenbach M; Nelius N; von Knebel Doeberitz M; Kloor M
    Fam Cancer; 2011 Sep; 10(3):557-65. PubMed ID: 21598004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
    Lam H; McNeil LK; Starobinets H; DeVault VL; Cohen RB; Twardowski P; Johnson ML; Gillison ML; Stein MN; Vaishampayan UN; DeCillis AP; Foti JJ; Vemulapalli V; Tjon E; Ferber K; DeOliveira DB; Broom W; Agnihotri P; Jaffee EM; Wong KK; Drake CG; Carroll PM; Davis TA; Flechtner JB
    Cancer Discov; 2021 Mar; 11(3):696-713. PubMed ID: 33504579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
    Hernandez-Sanchez A; Grossman M; Yeung K; Sei SS; Lipkin S; Kloor M
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Instability of a dinucleotide repeat in the 3'-untranslated region (UTR) of the microsomal prostaglandin E synthase-1 (mPGES-1) gene in microsatellite instability-high (MSI-H) colorectal carcinoma.
    Cherukuri DP; Deignan JL; Das K; Grody WW; Herschman H
    Mol Oncol; 2015 Aug; 9(7):1252-8. PubMed ID: 25817443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.